What happened with HIMS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Hims & Hers Health lets customers use its websites and apps to seek care for conditions such as hair loss, sexual health problems and weight management. Licensed medical providers assess customers and develop treatment plans; most prescriptions are filled by company-owned pharmacies, with partner pharmacies handling some orders. The platform also sells non-prescription health and wellness products.
Customers pay directly in most markets, rather than through insurers or government healthcare programs. Subscription purchases of prescription products and services account for the vast majority of U.S. revenue. Customers receive repeat shipments and are billed on their chosen schedule, but can pause or cancel under their subscription terms. The business therefore depends heavily on attracting customers through marketing and keeping them subscribed.
Hims & Hers relies on affiliated medical groups it does not own to deliver consultations. Restrictions on corporate medical practice leave clinical decisions with providers, while the company supplies non-clinical support. Medication availability is another constraint: certain weight-loss offerings rely primarily on one supplier. For compounded GLP-1 medicines, prepared for individual patients, the company currently uses only patient-specific compounding pharmacies. U.S. rules require an individual prescription establishing the need for the compounded drug and restrict copies of approved medicines, limiting what the company can offer and its capacity to meet demand.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Privately held Ro is an important direct-to-consumer rival missing from this list; Hims & Hers’ results hinge on keeping subscribers, acquiring customers affordably and maintaining access to personalized compounded treatments.
LifeMD competes with Hims & Hers for patients paying for recurring online care and prescription treatments in weight management, men’s health, hormone health and dermatology. Watch LifeMD’s weight-management subscribers: it had about 81,000 at December 31, 2025, a concrete measure of its reach in an overlapping market.
Novo Nordisk competes for weight-loss patients with branded obesity medicines, while its patent lawsuit directly threatens the compounded semaglutide treatments Hims & Hers sells through its online platform. Watch that case: Novo Nordisk filed it on February 9, 2026, and the claims could force Hims & Hers to stop offering affected treatments or seek a license.
Eli Lilly competes with Hims & Hers for weight-loss patients: Lilly sells branded obesity medicines including Zepbound, while Hims & Hers offers prescription treatments, including compounded medicines.
Teladoc Health competes with Hims & Hers for consumers seeking online mental-health care through BetterHelp, which sells counseling and therapy directly to consumers. BetterHelp is the business to watch for this overlap, rather than Teladoc’s Integrated Care services, which primarily sell to organizations.
Mangoceuticals competes with Hims & Hers for consumers buying pharmacy-prepared treatments through online consultations for erectile dysfunction, hair loss, weight management and hormone health; both are exposed to demand for personalized compounded medicines and the rules governing them. Watch access to Mangoceuticals’ Slim weight-management treatment, which contains semaglutide and is supplied only when a doctor determines that compounding is necessary for the individual patient.
Teladoc Health, Inc. earningsTDOC
Teladoc Health’s report will show how consumers are paying for BetterHelp’s online therapy, a direct measure of demand in a market where Hims & Hers also competes.
Look at BetterHelp’s customer and revenue trends. Growth in both would show that consumers are still paying for online therapy, supporting demand in a market Hims & Hers also serves; weakness would suggest that attracting and keeping customers in this shared market may be harder.
Hims & Hers Health, Inc. earningsThis company
Hims & Hers Health earns through recurring subscriptions to care and products, and its report will show whether subscriber growth and revenue per subscriber can continue without fulfillment costs eating into gross margin.
Read active subscribers, monthly revenue per average subscriber, and gross margin together. Rising subscriber numbers and revenue per subscriber with a steady margin would show that Hims & Hers is keeping customers and earning more per customer without costs outpacing revenue. Slower subscriber growth or another margin decline would point to retention or fulfillment costs constraining the subscription model.
